Boston Scientific Successfully Completes First ROTAPRO Rotational Atherectomy Procedure in Mainland China Following Product Launch
Boston Scientific
Medical Device Manufacturer
Source: Siyu MedTech
Reprint Requirements: Please indicate the source of the article at the beginning of the text, and it can be reprinted directly.
March 12, 2024Boston ScientificROTAPRORotational Atherectomy System Series (hereinafter referred to as“ROTAPROProduct Series”) InMainland ChinaThe first after listingExampleThe surgery was successfully carried out at Zhongshan Hospital Affiliated to Fudan University, markingROTAPROA New Chapter in Benefiting Chinese Patients Has Begun。Ge Junbo, Academician of the Chinese Academy of Sciences and Director of the Cardiology Department at Zhongshan Hospital Affiliated to Fudan UniversityLead，Prof. Qian Juying, Prof. Ma Jianying, Prof. Yao Kang, and Prof. Li Chenguang from his/her teamA total of4NameThe patient has completed the surgery.
Calcified lesions are one of the common characteristic pathological manifestations of coronary heart disease, and due to their hard texture and difficulty in being treated with conventional instruments, they have becomePercutaneousCoronary Intervention Treatment (PCI) One of the biggest challenges during surgery. Coronary Artery Plaque RotablationBy expertsConsensusRecommended asThe first choice for severe calcified lesions in coronary heart disease, but due to the relatively complex surgical operation,To the operatorThe requirements are relatively high, making it difficult to widely popularize in clinical settings. Targeting this pain point, Boston Scientific has broughtNewly UpgradedROTAPROProduct Series,A simple and user-friendly new product design can better help popularize and carry out coronary artery rotational atherectomy.Assistant SurgeonOvercome Clinical Application Challenges.
Postoperative,Academician Ge Junbo said:“China has more than1000Hundreds of millions of patients with coronary heart disease. As the aging of the population deepens, the incidence and number of patients with coronary heart disease will continue to rise in the future, bringing a heavy burden of disease to the whole society. I look forward toNewly Listed Coronary Rotablation ProductsAfter being put into clinical application in China, which can help grassroots better cope with the severe public health challenge of coronary artery calcification., alleviating patient suffering。”
As early as1994Year,Academician Ge JunboTake the leadCoronary Artery Plaque RotablationIntroductionInto China,UseFirst-generation CoronaryRotational Atherectomy SystemRotablatorCompleted the first caseSurgery,MarksCoronary Artery DiseaseIn ChinaTreatmentOpened a new path。RotablatorEvidence-based use in nearly three decades,Currently stillIs ChinaMainlandThe only classic product available on the market for coronary artery plaque旋磨术, which has been applied in tens of thousands of surgeries.
Relying on the mature system of previous-generation products and extensive clinical experience,ROTAPROThe series of products have achieved breakthroughs in the lightweight, intelligent, and portable aspects of rotational atherectomy interventional treatment devices. Among them, the core software of the operating system was designed and developed by a Chinese R&D team, making it more attuned to local needs and facilitating standardized operation techniques for doctors during the learning process.Before the official launch, Boston Scientific CorporationLeverage“Pilot First”With the policy boost, achieved in Hainan's Lecheng Pilot ZoneROTAPROClinical Series ProductsUse, benefiting patients in China。Brand New UpgradeROTAPROProduct Series LaunchWillChange Previous SpinGrinding TechnologyThe current situation of high barriers, the design concept of "easy to learn, easy to use, and easy to teach" alsoWillAssist this surgical procedureIn moreHospitalByUse,To be mastered by more surgeons,Truly benefit more Chinese patients through technological innovation.
Ms. Zhang Jun, President of Boston Scientific Greater China, stated:“As a pioneer in the field of coronary rotational atherectomy, Boston Scientific continuously updates and iterates its technology.ROTAPROThe series of products has currentlyInGlobally Widely Used. Subsequently2022We are very pleased to see that this cutting-edge technology has been officially and fully introduced into the Chinese market in just over a year after its clinical application in Hainan. We have always been committed toPCIThe promotion of technology and concepts, looking forward toROTAPROThe launch of the product series can accelerateCoronary Artery PlaqueThe Popularization and Implementation of Rotational Atherectomy Enhances Treatment Efficiency at the Grassroots LevelIn the future, Boston Scientific will continue to introduce innovative products and leading technologies, accelerating their accessibility in China.Sex, meanwhileEmpowerMedPatients' Growth, Benefiting Chinese Patients。”
Global MedTech TOP100: 2023 Global MedTech TOP100
2023 Global MedTech Industry Contribution Award
2023 Global Medical Technology Innovation Award
2023 Global MedTech Rising Star Award
2023 Global Innovative Medical Device Award
Editor-in-Chief | Zhao Qing Reviewed by | Yi He
